Latest Oligodendroglioma Stories
The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer.
A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer.
For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer.
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer.
CHICAGO, June 5 /PRNewswire/ -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Researchers have identified an important cancer gene that could lead to more effective drugs being developed to fight pediatric high grade glioma, a disease which currently has a poor prognosis.
MALVERN, Pa., Oct.
Chemotherapy alone is just as effective as radiation / New positive prognostic factor found.